Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

Lindsey R. Baden; Hana M. El Sahly; Brandon Essink; Dean Follmann; Kathleen M. Neuzil; Allison August; Heather Clouting; Gabrielle Fortier; Weiping Deng; Shu Han; Xiaoping Zhao; Brett Leav; Carla Talarico; Bethany Girard; Yamuna D. Paila; Joanne E. Tomassini; Florian Schödel; Rolando Pajon; Honghong Zhou; Rituparna Das; Jacqueline Miller

Journal ArticleOPEN ACCESS

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

Baden L
El Sahly H
Essink B
et al.

New England Journal of Medicine (2021) 385(26) 2485-2487

DOI: 10.1056/nejmc2115597

51Citations

61Readers

Abstract

mRNA-1273 Vaccine Efficacy against the Delta Variant Participants who had received placebo in a previous phase of this trial were offered the mRNA-1273 vaccine in the open-label phase. The incidenc...

Cite

CITATION STYLE

APA

Baden, L. R., El Sahly, H. M., Essink, B., Follmann, D., Neuzil, K. M., August, A., … Miller, J. (2021). Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge. New England Journal of Medicine, 385(26), 2485–2487. https://doi.org/10.1056/nejmc2115597

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

Abstract

Cite

Register to see more suggestions